Bosutinib Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 100 mg, 400 mg, 500 mg
Reference Brands: Bosulif (USA)
Category:
Oncology Cancer Care
Bosutinib is an oral tyrosine kinase inhibitor (TKI) used for the treatment of Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML). It works by blocking the BCR-ABL kinase enzyme that promotes the growth of cancerous white blood cells. Marketed under the brand name Bosulif, it is available as film-coated tablets in 100 mg, 400 mg, and 500 mg strengths. It is indicated for patients who are newly diagnosed or resistant/intolerant to prior TKI therapy.
Bosutinib is available in Tablets
and strengths such as 100 mg, 400 mg, 500 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Bosutinib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Bosutinib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing